1,4-dioxaspiro[4.5]dec-7-ene-8-carbaldehyde | 72445-22-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,4-dioxaspiro[4.5]dec-7-ene-8-carbaldehyde
• CAS: 72445-22-8
• 化学式: C₉H₁₂O₃
• 分子量: 168.192
• InChiKey: AWBSZGVCLQGHIZ-UHFFFAOYSA-N

物化性质

• 沸点：
  289.7±40.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,4-dioxaspiro[4.5]dec-7-ene-8-carbaldehyde 在 咪唑 、 盐酸 、 正丁基锂 、 palladium 10% on activated carbon 、 氢气 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 二氯甲烷 、 水 为溶剂， -78.0~50.0 ℃ 、101.33 kPa 条件下， 反应 76.06h， 生成 Bis(4-fluorocyclohex-3-en-1-yl)methanol
  参考文献：
  名称：

  Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy

  摘要：

  We designed and synthesized perhexiline analogues that have the same therapeutic profile as the parent cardiovascular drug but lacking its metabolic liability associated with CYP2D6 metabolism. Cycloalkyl perhexiline analogues 6a-j were found to be unsuitable for further development, as they retained a pharmacokinetic profile very similar to that shown by the parent compound. Multistep synthesis of perhexiline analogues incorporating fluorine atoms onto the cyclohexyl ring(s) provided a range of different fluoroperhexiline analogues. Of these, analogues 50 (4,4-gem-difluoro) and 62 (4,4,4',4'-tetrafluoro) were highly stable and showed greatly reduced susceptibility to CYP2D6-mediated metabolism. In vitro efficacy studies demonstrated that a number of derivatives retained acceptable potency against CPT-1. Having the best balance of properties, 50 was selected for further evaluation. Like perhexiline, it was shown to be selectively concentrated in the myocardium and, using the Langendorff model, to be effective in improving both cardiac contractility and relaxation when challenged with high fat buffer.

  DOI：

  10.1021/acs.jmedchem.6b01592
• 作为产物：
  描述：

  1,4-环己二酮单乙二醇缩酮 在 potassium tert-butylate 、 palladium diacetate 、 溶剂黄146 、 对苯醌 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 18.75h， 生成 1,4-dioxaspiro[4.5]dec-7-ene-8-carbaldehyde
  参考文献：
  名称：

  钯催化的烯醇醚的反应：接触Enals，呋喃和二氢呋喃

  摘要：

  描述了使用低负载量的钯催化剂的钯催化的烯醇醚氧化为烯醛。温和的氧化条件可耐受各种官能团，同时允许形成二，三和四取代的烯烃。该方法在含有侧链醇的烷基烯醇醚的分子内反应中的应用提供了呋喃和2，5-二氢呋喃产物。

  DOI：

  10.1021/ol3028994

文献信息

• Palladium‐Catalyzed Reductive Carbonylation of (Hetero) Aryl Halides and Triflates Using Cobalt Carbonyl as CO Source
  作者：Bhushanarao Dogga、C. S. Ananda Kumar、Jayan T. Joseph

  DOI：10.1002/ejoc.202001328

  日期：2021.1.15

  A generalized protocol for the reductive carbonylation of (hetero) aryl halides and triflates under CO gas‐free conditions using Pd/Co2(CO)8 and triethylsilane has been developed. The mild reaction conditions, enhanced safety, and wide substrate scope highlight its importance in routine organic synthesis.

  已经开发了一种通用协议，用于在无CO气体条件下使用Pd / Co 2（CO）8和三乙基硅烷对（杂）芳基卤化物和三氟甲磺酸进行还原羰基化。温和的反应条件，增强的安全性和广泛的底物范围突出了其在常规有机合成中的重要性。
• Pd-Catalyzed Carbonylation of Vinyl Triflates To Afford α,β-Unsaturated Aldehydes, Esters, and Amides under Mild Conditions
  作者：Shaoke Zhang、Helfried Neumann、Matthias Beller

  DOI：10.1021/acs.orglett.9b00765

  日期：2019.5.17

  An efficient and general protocol for the synthesis of α,β-unsaturated aldehydes, esters, and amides via carbonylation of vinyl triflates including derivatives of camphor, ketoisophorone, verbenone, and pulegone was developed. Crucial for these transformations is the use of a specific palladium catalyst containing a pyridyl-substituted dtbpx-type ligand. This procedure also allows for an easy access

  开发了一种有效的通用方案，可通过乙烯基三氟甲磺酸酯的羰基化反应合成α，β-不饱和醛，酯和酰胺，包括樟脑，酮异佛尔酮，马鞭草酮和普乐酮。这些转化的关键是使用含有吡啶基取代的d t bpx型配体的特定钯催化剂。该方法还使得容易从相应的酮获得二羰基化产物。
• A general approach to crinine-type Amaryllidaceae alkaloids: total syntheses of (±)-haemanthidine, (±)-pretazettine, (±)-tazettine, and (±)-crinamine
  作者：Fu-Min Zhang、Yong-Qiang Tu、Jian-Dong Liu、Xiao-Hui Fan、Lei Shi、Xiang-Dong Hu、Shao-Hua Wang、Yong-Qiang Zhang

  DOI：10.1016/j.tet.2006.07.027

  日期：2006.10

  A general strategy for synthesizing the crinine-type Amaryllidaceae alkaloids was developed. And total syntheses of four representative crinine-type Amaryllidaceae alkaloids: (±)-haemanthidine, (±)-pretazettine, (±)-tazettine, and (±)-crinamine, were accomplished via a common intermediate 17. This crucial precursor was achieved on the basis of the NBS-promoted semipinacol rearrangement recently developed

  提出了合成可丽宁型金莲花科生物碱的一般策略。和的四个代表性crinine型全合成石蒜科生物碱：（±）-haemanthidine，（±）-pretazettine，（±）-tazettine，和（±）-crinamine，分别经由公共中间完成17。这个关键的前体是在我们的研究小组最近开发的NBS促进的半松果醇重排和分子内迈克尔加成的基础上实现的，后者分别有效地构建了可瑞宁型生物碱的空间拥挤的季碳中心和氢吲哚骨架。
• Saegusa Oxidation of Enol Ethers at Extremely Low Pd-Catalyst Loadings under Ligand-free and Aqueous Conditions: Insight into the Pd(II)/Cu(II)-Catalyst System
  作者：Quan Zhu、Yunsong Luo、Yongyan Guo、Yushun Zhang、Yunhai Tao

  DOI：10.1021/acs.joc.0c02987

  日期：2021.4.16

  system of Saegusa oxidation, which converts enol ethers to the corresponding enals with a number of diverse substrates at extremely low catalyst loadings (500 mol ppm) under ligand-free and aqueous conditions, is described. Its synthetic utility was demonstrated by large-scale applications of the catalyst system to important nature molecules. This work allows Saegusa oxidation to become a highly practical

  Saegusa氧化的高效实用的Pd（II）/ Cu（OAc）2-催化剂体系，可在无配体的情况下以极低的催化剂负载量（500 mol ppm）将烯醇醚转化为具有多种底物的相应烯醛和水性条件，描述。催化剂体系在重要的自然分子上的大规模应用证明了其合成用途。这项工作使Saegusa氧化成为制备enals的一种高度实用的方法，并且还为对Pd（II）/ Cu（II）-用于羰基化合物脱氢和降低Pd-催化剂负载量的催化剂体系提出了新的见解。
• [EN] FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE<br/>[FR] COMPOSÉS DE FLUORO-PERHEXILINE ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：UNIV ABERDEEN

  公开号：WO2014184561A1

  公开（公告）日：2014-11-20

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain fluoro-perhexiline compounds of the following formula (also referred to herein as FPER compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, for example, those which are known to be treated with, or known to be treatable with, perhexiline, including, for example, disorders that are ameliorated by the inhibition of carnitine palmitoyltransferase (CPT); cardiovascular disorders such as: angina pectoris; heart failure (HF); ischaemic heart disease (IHD); cardiomyopathy; cardiac dysrhythmia; stenosis of a heart valve; hypertrophic cardiomyopathy (HCM); coronary heart disease; and other disorders, for example, diabetes and cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及以下式（在本文中也称为FPER化合物）的某些氟代perhexiline化合物，例如用于治疗包括已知可用perhexiline治疗或已知可用perhexiline治疗的紊乱（例如疾病），包括通过抑制肉碱棕榈酰基转移酶（CPT）改善的紊乱，如：心绞痛；心力衰竭（HF）；缺血性心脏病（IHD）；心肌病；心脏心律失常；心脏瓣膜狭窄；肥厚型心肌病（HCM）；冠心病；以及其他疾病，例如糖尿病和癌症。本发明还涉及包括这些化合物的药物组合物，以及这些化合物和组合物的用途，例如在治疗中的用途。